Interpace Biosciences, Inc.
corporate_fare Company Profile
Interpace Biosciences, Inc. (OTC:IDXG) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for IDXG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for IDXG spans S-1/A, 10-Q, DEF 14A, PRE 14A.
Recent high-impact activity:
- Interpace Prices 3.1M-Share Nasdaq Uplist Offering at $6.00-$7.00
- Interpace Biosciences Guides Q3 Revenue Up 11-14% Sequentially to $10.1M-$10.4M
- Interpace Biosciences Announces Reverse Split to Support Nasdaq Uplisting
- Interpace Biosciences Swings to Q2 Profit as Thyroid Business Grows 9%
- Interpace Q2 Revenue Dips 1% but Thyroid Business Grows 9%, Margins Expand
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2 shares in IDXG as of the October 15, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume. On November 5, 2026, 28.8% of IDXG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IDXG, detected from its recent SEC filings · based on capital-structure filings through 2026-10-30.
3.1M-Share Underwritten Offering Launched · About $17.9M Net Proceeds at Midpoint
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →